DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 2.95 EUR 9.06%
Market Cap: 530.5m EUR

DBV Technologies SA
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DBV Technologies SA
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
DBV Technologies SA
PAR:DBV
Total Receivables
$15.7m
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
6%
Valneva SE
PAR:VLA
Total Receivables
€24.1m
CAGR 3-Years
14%
CAGR 5-Years
26%
CAGR 10-Years
7%
Nanobiotix SA
PAR:NANO
Total Receivables
€9.1m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Inventiva SA
PAR:IVA
Total Receivables
€12.5m
CAGR 3-Years
-11%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Total Receivables
$29.4m
CAGR 3-Years
31%
CAGR 5-Years
19%
CAGR 10-Years
6%
Eurobio Scientific SA
PAR:ALERS
Total Receivables
€38m
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
15%
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
530.5m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
8.03 EUR
Undervaluation 63%
Intrinsic Value
Price

See Also

What is DBV Technologies SA's Total Receivables?
Total Receivables
15.7m USD

Based on the financial report for Jun 30, 2025, DBV Technologies SA's Total Receivables amounts to 15.7m USD.

What is DBV Technologies SA's Total Receivables growth rate?
Total Receivables CAGR 10Y
6%

Over the last year, the Total Receivables growth was -24%. The average annual Total Receivables growth rates for DBV Technologies SA have been 13% over the past three years , 24% over the past five years , and 6% over the past ten years .

Back to Top